Converge Bio, a generative artificial intelligence startup focused on drug development, announced the completion of a $25 million Series A funding round led by Bessemer Venture Partners. The company leverages AI trained on molecular data to accelerate drug development. Since its seed round in 2024, it has experienced rapid growth, currently partnering with 40 industry collaborators and employing 34 staff. Its platform integrates generative and predictive models for antibody design and protein optimization, helping partners significantly improve efficiency. CEO Dov Gertz pointed out that the industry is undergoing a major shift from trial-and-error methods to data-driven design, which positions Converge to become a foundational "generative AI laboratory" in the life sciences field.